高清福利片

New research has demonstrated the safety of bacteriophage therapy in treating severe Staphylococcus aureus infections in the blood.

The findings, published in area step forward in the fight against antibiotic resistance.

Bacteriophages or 鈥榩hages鈥� are viruses that selectively attack bacteria. Bacteriophage therapy, or 鈥榩hage therapy鈥� for short has been used therapeutically in the past to treat bacterial infections but never in a controlled trial setting. The use of bacteriophage therapy was largely replaced when antibiotics became widely available.

Phage therapy is when a preparation containing bacteriophages tailored to target a certain bacteria are administered to patients. 聽

As bacterial infections are growing increasingly resistant to current antibiotic treatments, researchers are now revisiting the potential of phage therapy as a form of treatment.

Lead researcher on the study, from the (WIMR) and the University of Sydney said, 鈥淎ntibiotic resistance is a rapidly emerging threat to global health. Because of this, phage therapy is experiencing a renaissance.鈥�

鈥淲e know that phage therapy has the potential to treat infections, but evidence of its safety and effectiveness, particularly from clinical trials, is currently limited.

鈥淥ur study investigated whether phage therapy is safe in treating severe Staphylococcus aureus 产补肠迟别谤补别尘颈补.鈥�

Staphylococcus aureus bacteraemia occurs when the Staphylococcus aureus bacteria enters the bloodstream. This can lead to life-threatening conditions, including infective endocarditis (an infection of the heart) and sepsis (a severe immune response to infection).

In the study, the research team administered phage therapy intravenously to 13 patients who had severe Staphylococcus aureus infections. The patients also received treatment with antibiotics at the same time.

Professor Iredell said, 鈥淥ur patients did not show any signs of adverse reaction from the phage therapy. 鈥�

鈥淚mportantly, our phage was produced under Goods Manufacturing Practices (GMP), which ensure the quality of therapeutic products.

鈥淭his is the first time that research has been able to show that IV-administered phage therapy, produced under GMP conditions is safe and well-tolerated in people with severe Staphylococcus aureus 颈苍蹿别肠迟颈辞苍蝉.鈥�

Rates of antibiotic resistance are increasing worldwide, making it harder to treat common infections, such as urinary tract infections, and certain sexually transmissible infections.

鈥淚f we can鈥檛 combat this threat, we may reach a point where infections that were previously simple to treat will become untreatable,鈥� Professor Iredell said.

鈥淎ntibiotic resistance is a huge threat to our health system 鈥� we wouldn鈥檛 be able to perform certain life-saving treatments, such as transplantation and cancer therapy, without effective treatment against infections.

鈥淢ore evidence in support of phage is still needed before it鈥檚 offered to patients on a larger scale.

鈥淗owever, our study makes it clear that it could, potentially, offer a safe treatment for serious infections, and help reduce the impact of antibiotic resistance,鈥� he concluded.

The research, led by Professor Jon Iredell was a collaboration between the University of Sydney, the Westmead Institute of Medical Research and the University of New South Wales.聽

Declaration: No personal financial interest was received by the researchers. A provisional patent has been filed in the United States and selected authors are listed among the inventors. ABPH is the sole proprietary owner of AB-SA01. Professor Iredell has previously acted as a clinical advisor to C3J Therapeutics. C3J Therapeutics and ABPH announced a merger on 4 January 2019 to become Armata Pharmaceuticals. For full details refer to .听听听听听听听